enzon pharmaceuticals
enzon pharmaceuticals' s revenue was reported to be $ 8. 38 m in fy, 2016
enzon pharmaceuticals, inc. ’s iss governance qualityscore as of n / a is n / a .
note to media and investors belrose pharma has been formed by new investors to develop pharmaceutical products with technologies and clinical programs acquired from enzon pharmaceuticals and others. the belrose pharma investors have no substantive relationship to any major equity or debt holder in enzon pharmaceuticals. enzon pharmaceuticals also does not have any equity ownership in belrose pharma .
you are requesting a prediction for the closing price for enzon pharmaceuticals (enzn) for 2018 - 07 - 10 .
for enzon: andrea rabney argot partners 212. 600. 1902 email contact for hisun: zhang wei zhejiang hisun pharmaceuticals (86571) 8527 8141 email contact
after selling out in the second quarter, carl icahn (trades, portfolio) acquired an even larger position in enzon pharmaceuticals (enzn) on nov. 28 .
after selling out in the second quarter, carl icahn (trades, portfolio) acquired an even larger position in enzon pharmaceuticals (enzn) on nov. 28 .
enzon pharmaceuticals, inc. manages its sources of royalty revenues from existing licensing arrangements with other companies primarily related to sales of certain drug products that utilize our proprietary technology .
genzyme is the biotech industry’s second - largest company, with revenues of $ 4. 5 billion and a market capitalization of about $ 13 billion. previously, mr. icahn has taken on smaller companies: biogen - idec, medimmune, imclone systems, amylin pharmaceuticals and enzon pharmaceuticals .
enzon pharmaceuticals, inc. is a biotechnology company dedicated to the research and development of innovative therapeutics for patients with high unmet medical need. enzon’s drug - development programs utilize two platforms: customized pegylation linker technology (customized linker technology®) and third - generation mrna - targeting agents utilizing the locked nucleic acid (lna) technology. enzon currently has four compounds in human clinical development and multiple novel mrna antagonists in preclinical research. enzon receives royalty revenues from licensing arrangements with other companies related to sales of products developed using its proprietary customized linker technology. further information about enzon and this press release can be found on the company’s website at urltoken .
new york, ny / accesswire / march 5, 2018 / latest key findings by growth market report for all traders, shareholders, and investors of vet online supply, inc. (otc pink: vtnl) and enzon pharmaceuticals ...
enzon pharmaceuticals, inc. is a biopharmaceutical company, which engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. the company was founded on september 17, 1981 and is headquartered in cranford, nj .
craig brings a wealth of knowledge and experience to enzons executive management team,  said jeffrey h. buchalter, enzons chairman and chief executive officer. i am confident his extensive industry experience across multiple disciplines will be an invaluable asset as we define and execute our strategy for driving enzon to its next stage of growth. 
piscataway, nj and zhejiang, china — (marketwire) — 05 / 07 / 12 — enzon pharmaceuticals, inc. (nasdaq: enzn) and zhejiang hisun pharmaceuticals co. ltd (sse code: 600267), a leading chinese pharmaceutical company, announced today a long - term strategic research, development and licensing collaboration. the agreement provides for the research and development of therapeutics using enzon’s customized pegylation linker technology. the agreement also includes the license to hisun of development and commercialization rights for enzon’s peg - sn38 (ezn - 2208), a novel, phase ii pegylated version of sn38, in the territory of china .
bridgewater, new jersey, january 5, 2005  enzon pharmaceuticals, inc. (nasdaq: enzn) today announced that craig tooman has been appointed executive vice president strategic planning and corporate communications. mr. tooman will report to enzons chairman and chief executive officer, jeffrey buchalter, and joins mr. buchalter and kenneth zuerblis, enzons executive vice president finance and chief financial officer, as an executive officer of the company. he will oversee enzons public relations, investor relations, and strategic planning functions. prior to joining enzon, mr. tooman served as senior vice president, strategic planning and corporate communications of ilex oncology, inc. , which was acquired by genzyme corporation (nasdaq: genz) in december 2004 .
enzon pharmaceuticals, inc. , together with its subsidiaries, engages in licensing drug products. its marketed drug products include pegintron for use in the treatment of chronic hepatitis c; and sylatron for use in the treatment of melanoma disease. the company was founded in 1981 and is headquartered in cranford, new jersey .
meanwhile, two smaller biotechnology companies, enzon and amylin, have also experienced mr. icahn’s challenges. since he urged the spinoff of enzon’s biotechnology business in 2007, mr. icahn has been successful in adding two directors and dr. denner was elected chairman of enzon’s board. at amylin, its chief executive, joseph cook, was forced out in 2009 after mr. icahn won two board seats .
enzon pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat life - threatening diseases. the company has developed or acquired a number of marketed products, including peg - intron (r), marketed by schering - plough, and abelcet (r), oncaspar (r), adagen (r), and depocyt (r), marketed in north america by enzons specialized sales force. enzons science - driven strategy includes an extensive drug development program that leverages the companys macromolecular engineering technology platforms, including peg modification and single - chain antibody (sca (r) ) technologies. internal research and development efforts are complemented by strategic transactions that provide access to additional marketed products and promising clinical compounds. enzon has several drug candidates in various stages of development, independently and with partners. further information about enzon can be found on the companys web site at urltoken .
enzon pharmaceuticals has pegged its future on researching ways to fight cancer. the company is focused on developing compounds using its pegylation technology and other platforms to improve the performance and deliverability of existing cancer drugs. pegylation involves custom attaching polyethylene glycol (peg) to a drug compound in order to make it more effective and less toxic for patients... .
enzon pharmaceuticals is the lower part of a horizontal trend on short term, and normally this would pose a good buying opportunity, though a break down through the bottom trend line at $ 0. 26 will give a strong sales signal and a trend shift may be expected. given the current horizontal trend you can expect enzon pharmaceuticals with 90% probability to be traded between $ 0. 26 and $ 0. 28 at the end of this period with 90% probability. a break of a horizontal trend is often followed by a large increase in the volume, and stocks seldom manage to go directly from the bottom of a trend up to the roof. stocks turning up in the middle of a horizontal trend are therefore considered to be potential runners .
while the company delisted earlier this year, it is still available as an over - the - counter stock. on thursday, enzon closed at 45 cents .
enzon is a biotechnology company dedicated to the research and development of innovative therapeutics for cancer patients with high unmet medical needs. the original enzon mark was something that resembled a cell with tentacles and a logotype that was dated. a rebranding effort was needed. a more streamlined font would give enzon’s identity a more contemporary look. optima was that font. we customized the “e” by attaching it to the “n” to form a unified ligature for a more innovative appeal. developing pharmaceuticals that targeted the human cell was best represented by the “o” in the logotype. management suggested a mark that would portray a company that was on the move—agile and forward - looking. an arrowhead placed within the “o” effectively represented this idea .
“hisun is a dynamic company with an aggressive strategy for expanding its portfolio of innovative therapeutics. we are very excited about this partnership and we look forward to advancing a variety of next - generation therapeutics with hisun in china and for enzon in other territories around the world, ” said ana stancic, principal executive officer of enzon. “enzon’s broad portfolio of proprietary permanent and releasable pegylation linker technology and decades of know - how offer unmatched, clinically and commercially validated capabilities for the enhancement of existing therapies to create novel, high - value product candidates, including bio - betters. ”
, according to activist shareholders. honestly, i felt a little guilty last month for criticizing enzon' s $ 250, 000 to $ 500, 000 per year price for ada - scid drug
enzon pharmaceuticals receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, pegintron®, sylatron®, macugen® and cimzia®. pegintron® is used for the treatment of chronic hepatitis c. sylatron® is used for the treatment of melanoma. macugen® is used for the treatment of neovascular (wet) age - related macular degeneration. cimzia® is used for the treatment of crohn' s disease and rheumatoid arthritis. co. has no clinical operations and limited corporate operations .
subsequent to the completion of this acquisition, several members of the core technical team that was formerly involved in enzon’s extensive research, development, and commercialization of the permanent and releasable customized linker technology® have joined belrose pharma .
( pegadamase bovine) after readers pointed out that as an ultra - orphan disease, enzon has to charge that much to make a profit. but maybe they could charge less if they reconsidered their executive pay policies .
enzon pharmaceuticals receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, pegintron®, sylatron®, macugen® and cimzia®. pegintron® is used for the treatment of chronic hepatitis c. sylatron® is used for the treatment of melanoma. macugen® is used for the treatment of neovascular (wet) age - related macular degeneration. cimzia® is used for the treatment of crohn' s disease and rheumatoid arthritis. co. has no clinical operations and limited corporate operations. according to our enzn split history records, enzn has had 1 split .
enzon pharmaceuticals receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, pegintron, sylatron, macugen and cimzia. the primary source of the company’s royalty revenues is sales of pegintron, which is marketed by merck & co. the company currently has no clinical operations and limited corporate operations. the company was previously dedicated to the research and development of innovative therapeutics for patients with high unmet medical needs. the company wound down its remaining research and development activities during 2013 and has no intention of resuming any clinical development activities or acquiring new sources of royalty revenues .
such forward - looking statements are based upon management’s present expectations, objectives, anticipation, plans, hopes, beliefs, intentions or strategies regarding the future and are subject to known and unknown risks and uncertainties that could cause actual results, events or developments to be materially different from those indicated in such forward - looking statements. a more detailed discussion of these and other factors that could affect results is contained in enzon’s filings with the u. s. securities and exchange commission, including enzon’s annual report on form 10 - k for the year ended december 31, 2011. these factors should be considered carefully and readers are cautioned not to place undue reliance on such forward - looking statements. no assurance can be given that the future results covered by the forward - looking statements will be achieved. all information in this press release is as of the date of this press release and enzon does not intend to update this information .
management revealed it is expecting to receive a cumulative amount of $ 21 million in royalty revenues between the beginning of 2016 and 2021. many expect the company to liquidate after this point. icahn may be interested in enzon for this very reason. the company already distributes special dividends throughout the year so its final liquidation may prove to be especially beneficial to shareholders .
under the terms of the strategic research, development and licensing collaboration, hisun will pay enzon to apply its customized pegylation linker technology, especially its releasable pegylation technology, and know - how to the development of next - generation, pegylated versions of select therapeutic candidates within hisun’s pipeline. once successfully pegylated, hisun will have the option to in - license the product candidates, based upon internal selection criteria, and will be fully responsible for funding development and commercialization of these products in the territory of china. under this agreement, enzon is entitled to milestone payments and a high - single - digit royalty on net sales for any product developed and commercialized in china, in addition to retaining rights to all pegylated compounds outside of china .
enzon is actively pursuing strategic partnerships with leading biotechnology and pharmaceutical companies worldwide whose marketed, development, or discovery - stage products may benefit from the enhanced pharmaceutical properties of pegylation. “our pegylation platform, combined with our extensive know - how, continues to be the gold standard for maximizing the therapeutic potential of both small molecules and biologics, ” says ms. stancic .
belrose will leverage the value of the assets purchased from enzon within belrose’s two key business areas: (a) advancing development of internal clinical and pre - clinical compounds, and (b) product development for third party customers seeking to improve both early clinical and mid - lifecycle products using customized linker technology®, where alternative technologies such as nanoparticles and lipid formulations are less suitable .
“this acquisition of enzon’s permanent and releasable customized linker technology® significantly strengthens our platform for accelerating the development of more patient - friendly and effective therapies in a range of specialty disease categories, ” said belrose pharma founder and ceo, eric gilbert. “we look forward to being a positive force for bringing new therapies and improved formulations of existing therapies to the global healthcare marketplace and to critically ill patient populations. ”
hua bai, ceo and chairman of hisun, added, “enzon’s pegylation technology is utilized in approved products generating a combined total of over $ 7 billion in annual sales, making them the partner of choice for validated pegylation technology. in addition to obtaining rights to peg - sn38, this partnership provides hisun access to innovative technology and development capabilities that will allow us to deliver novel therapeutics to the rapidly growing pharmaceutical market in china. ”
enzon was formerly a research stage biopharmaceutical company known for its customized pegylation linker technology. pegylation is used in the development of drugs to improve characteristics like solubility, reduced dosage, stability and lower toxicity. it now has no clinical operations and very limited corporate operations. currently, it is surviving off royalty streams from products that incorporate this technology. these products include pegintron, sylatron, macugen and cimzia. the company also ran a products and manufacturing division but divested it in 2010 .
about pegylation technology pegylation technology has successfully enabled regulatory approval and launch of a series of breakthrough pharmaceutical products since enzon first pioneered the technique in the 1980s. since fda approval of the first pegylated product, adagen® (peg - bovine adenosine deaminase) in 1990, cumulative worldwide revenue of all pegylated pharmaceutical products has exceeded $ 20 billion. pegylation has been validated for compounds including enzymes, peptides, small molecules and antibody fragments, with the chemical attachment of polyethylene glycol (peg) used to improve those compounds’ half lives and toxicity profiles, among other patient benefits achieved by maximizing the inherent biological activity of the native molecules .
in contrast, enzon’s profitability and growth was ranked 4 of 10 by gurufocus. it has an operating margin of 78. 3% and a net margin of 149. 6% . the return on equity (roe) and return on assets (roa) outperform 99% of other biotechnology companies. the return on capital (roc) outperforms 100% of competitors. where the company falls short is its three - year revenue growth of - 24. 3% . this figure underperforms 76% of competitors. additionally, the company has a one - star predictability rating, which means it is hard to predict future results .
princeton, nj, june 19, 2013 – in its first major deal, belrose pharma, a new specialty pharmaceutical company dedicated to advancing development of the next generation of innovative injectable and sustained release drug therapies in patient disease populations with high unmet medical needs, today announced the acquisition of enzon pharmaceutical’s pegylation linker technology (customized linker technology®) platform and associated product pipeline. acquisition of this technology will enable belrose pharma to accelerate creation of improved biologic and small molecule therapies with better treatment outcomes for patients with life - threatening diseases such as breast cancer and pediatric neuroblastoma, and orphan drug diseases such as hereditary angioedema (hae) .
in contrast, enzon' s profitability and growth was ranked 4 of 10 by gurufocus. it has an operating margin of 78. 3% and a net margin of 149. 6% . the return on equity (roe) and return on assets (roa) outperform 99% of other biotechnology companies. the return on capital (roc) outperforms 100% of competitors. where the company falls short is its three - year revenue growth of - 24. 3% . this figure underperforms 76% of competitors. additionally, the company has a one - star predictability rating, which means it is hard to predict future results .
dr. kostas has been a director of our company since september 25, 2013. since january 2016, dr. kostas has been a senior analyst at sarissa capital management lp, an investment firm focused on the health care industry. prior to joining sarissa capital management lp, dr. kostas covered the biotechnology and pharmaceutical industries, most recently as director, at evercore isi (formerly known as international strategy & investment), a full service broker - dealer that provides macro and fundamental research, sales, and trading services to customers. previously, he practiced internal medicine as part of the yale new haven health system and was engaged as a consultant to various biotechnology companies. in addition, from 2010 to 2011, dr. kostas served as a member of the board of directors of mast therapeutics (then known as adventrx pharmaceuticals). dr. kostas received his s. b. degree from the massachusetts institute of technology and his m. d. degree from the university of texas southwestern medical school .
hisun has also acquired exclusive development and commercialization rights to peg - sn38 in china and will pay enzon an undisclosed upfront fee, milestone payments and a high - single - digit royalty on net sales. further financial terms were not disclosed. peg - sn38 has completed phase ii clinical trials in the united states where it was studied as a treatment for metastatic breast cancer, colorectal cancer and solid tumors in pediatric cancer patients. it is a pegylated conjugate of sn38, the active metabolite of the widely used anti - cancer drug irinotecan. peg - sn38 offers therapeutic advantages over unmodified sn38, including increased solubility, higher exposure and tumor accumulation, more profound deoxyribonucleic acid (dna) damage, inhibition of angiogenesis and longer apparent half - life of sn38 as compared to irinotecan .
belrose will continue development of two programs acquired from enzon. the first program is peg - sn38 (formerly ezn - 2208), a phase iii - ready pegylated conjugate of sn38 with improved properties including parenteral delivery, increased solubility, higher exposure, more profound deoxyribonucleic acid (dna) damage, inhibition of angiogenesis, and longer half - life compared with native sn38. peg - sn38 produced positive responses in clinical trials for metastatic breast cancer and pediatric neuroblastoma. the second program is peg - c1 esterase inhibitor (formerly ezn - 3008), a preclinical pegylated form of plasma - derived c1 - esterase inhibitor (c1 - inh) offering the significant improvement of weekly or bi - weekly subcutaneous or intravenous injections to hae patients currently limited to twice - weekly infusions for prophylactic use .
and compensation values are for the last fiscal year ending on that date. pay is salary, bonuses, etc. exercised is the value of options exercised during the fiscal year. currency in usd .
the pillar scores are audit: n / a; board: n / a; shareholder rights: n / a; compensation: n / a .
scores indicate decile rank relative to index or region. a decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk .
jul 9, 2018 1: 35 pm edt. 15 minute delayed data provided by nasdaq
we' re sorry this is all we were able to find about this topic .
html public
- / / w3c / / dtd xhtml 1. 0 transitional / / en
urltoken
we' re sorry we weren' t able to find anything about this topic .
html public
- / / w3c / / dtd xhtml 1. 0 strict / / en
urltoken
html public
- / / w3c / / dtd html 4. 0 transitional / / en
urltoken
he bought 6, 598, 886 shares for an average cost of 41 cents per share. this represents nearly 15% of the company’s outstanding shares but only accounts for 0. 01% of his total assets managed .
warning! gurufocus has detected 2 warning signs with enzn. click here to check it out .
the new jersey - based biopharmaceutical company has a market cap of $ 19. 9 million and an enterprise value of $ 7. 12 million. it has a price - earnings (p / e) ratio of 1. 4, a price - book (p / b) ratio of 0. 9 and a price - sales (p / s) ratio of 1. 9 .
gurufocus ranked the company’s financial strength 8 of 10. the piotroski f - score of 5 and altman z - score of 68. 12 suggest the company is financially stable. the return on invested capital (roic) outperforms the weighted average cost of capital (wacc) so the company is creating value as it grows. in addition, the company has no debt .
the stock reached its all - time high of $ 77. 94 in november of 2000. since then, the stock has declined significantly. in april of 2002, the stock was trading around $ 40 and fell to $ 28. 73 by the end of may that same year. from there, the stock continued its gradual decline with only a few surges throughout the next several years. within the past six years, the highest price the stock has reached was $ 12. 16 on dec. 31, 2010. it has been trading under $ 2 since august 2013 .
icahn has a long history with the company that dates back prior to the first quarter of 2010 .
disclosure: i do not own stock in any companies mentioned in the article .
i am an editorial assistant at gurufocus. i have a ba in journalism and a ma in mass communications from texas tech university. i have lived in texas most of my life, but also have roots in new mexico and colorado. follow me on twitter! @ gurusydneeg
get wordpress plugins for easy affiliate links on stock tickers and guru names | earn affiliate commissions by embedding gurufocus charts gurufocus affiliate program: earn up to $ 400 per referral. (learn more )
disclaimers: urltoken is not operated by a broker, a dealer, or a registered investment adviser. under no circumstances does any information posted on urltoken represent a recommendation to buy or sell a security. the information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. the gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. in no event shall urltoken be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on urltoken, or relating to the use of, or inability to use, urltoken or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. past performance is a poor indicator of future performance. the information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. the information on this site is in no way guaranteed for completeness, accuracy or in any other way. the gurus listed in this website are not affiliated with urltoken, llc. stock quotes provided by interactive data. fundamental company data provided by morningstar, updated daily .
html public
- / / w3c / / dtd html 4. 01 transitional / / en
urltoken
if the video does not load after a few moments, upgrade to the latest flash player .
nothing in dividend channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by bnk invest inc. or any of its affiliates, subsidiaries or partners. none of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. all viewers agree that under no circumstances will bnk invest, inc, . its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. by visiting, using or viewing this site, you agree to the following
enter up to 25 symbols separated by commas or spaces in the text box below. these symbols will be available during your session for use on applicable pages .
don' t know the stock symbol? use the symbol lookup tool. alphabetize the sort order of my symbols
sign up now to become a urltoken member and begin receiving instant notifications when key events occur that affect the stocks you follow .
the dividend history page provides a single page to review all of the aggregated dividend payment information. visit our dividend calendar: our partner, zacks investment research, provides the upcoming ex - dividend dates for the next month .
dividend history information is presently unavailable for this company. this could indicate that the company has never provided a dividend or that a dividend is pending .
please note that once you make your selection, it will apply to all future visits to nasdaq. com. if, at any time, you are interested in reverting to our default settings, please select default setting above. if you have any questions or encounter any issues in changing your default settings, please email isfeedback @ urltoken .
you have selected to change your default setting for the quote search. this will now be your default target page; unless you change your configuration again, or you delete your cookies. are you sure you want to change your settings ?
please disable your ad blocker (or update your settings to ensure that javascript and cookies are enabled), so that we can continue to provide you with the first - rate market news and data you' ve come to expect from us .
html public
- / / w3c / / dtd html 4. 01 transitional / / en
html public
- / / w3c / / dtd xhtml 1. 0 strict / / en
urltoken
s & p 500 index data: s & p 500 copyright © 2018 currency is displayed in usd .
international sites: australia canada china france germany hong kong italy the netherlands norway spain u. k. switzerland
independent. insightful. trusted. morningstar provides stock market analysis; equity, mutual fund, and etf research, ratings, and picks; portfolio tools; and option, hedge fund, ira, 401k, and 529 plan research. our reliable data and analysis can help both experienced enthusiasts and newcomers. © copyright morningstar, inc. all rights reserved. please read our terms of use and privacy policy. dow jones industrial average, s & p; 500, nasdaq, and morningstar index (market barometer) quotes are real - time. russell 2000 quote is 10 minutes delayed .
html public
- / / w3c / / dtd html 4. 01 / / en
urltoken
copyright © quotemedia. data delayed 15 minutes unless otherwise indicated. view delay times for all exchanges. market data powered by quotemedia. see the quotemedia terms of use .
the overall rating is a weighted average of the three other rated categories listed below. it is a general indication of the health of a dividend .
this indicator measures a stock' s current dividend yield, and compares it to similar stocks and historical yields .
the rating for dividend history is determined by looking back at the frequency and amount of historical dividend payments .
this indicator measures a stock' s history of dividend increases; consistent increases over time will produce a favorable rating .
information / data on this site is provided' as is' and for informational purposes only. please read our disclaimer and complete terms of use .
database. the split for enzn took place on september 29, 2017. this was a 5 for 3 split, meaning for each 3 shares of enzn owned pre - split, the shareholder now owned 5 shares. for example, a 1000 share position pre - split, became a 1666. 66666666667 share position following the split .
when a company such as enzn splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. often, however, a lower priced stock on a per - share basis can attract a wider range of buyers. if that increased demand causes the share price to appreciate, then the total market capitalization rises post - split. this does not always happen, however, often depending on the underlying fundamentals of the business. looking at the enzn split history from start to finish, an original position size of 1000 shares would have turned into 1666. 66666666667 today. below, we examine the compound annual growth rate — cagr for short — of an investment into enzn shares, starting with a $ 10, 000 purchase of enzn, presented on a split - history - adjusted basis factoring in the complete enzn split history .
enzn split history | www. split history. com | copyright © 2013 - 2018, all rights reserved
is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by bnk invest inc. or any of its affiliates, subsidiaries or partners. split history database is not guaranteed to be complete or free of errors. none of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. all viewers agree that under no circumstances will bnk invest, inc, . its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. by visiting, using or viewing this site, you agree to the following
ms. mcnealey has been a director of our company since september 25, 2013. since december 2016, ms. mcnealey has been vice president, investor relations and strategy of calithera biosciences, inc. from february 2015 to december 2016, ms. mcnealey was senior director investor relations and serves as a member of the management team at calithera biosciences, inc. prior to joining calithera biosciences, inc. , ms. mcnealey served as an advisor to biotechnology companies. in 2005, ms. mcnealey founded laurient llc, a research company focused on the biotechnology and pharmaceutical industries, where she worked until 2012. prior to founding laurient llc, ms. mcnealey served as a portfolio manager and biotechnology analyst at various firms, including paramount capital, franklin templeton, amerindo investment advisors and morgan stanley dean witter advisors. ms. mcnealey has a b. a. and an m. h. a. from cornell university .
phone: 1 732 9804500 fax: 13 - 02 - 6555049 urltoken no. employees: 01 turnover: 08. 38 (us $ m) financial year end: december
know more about this business than we do? cool! please submit any corrections or missing details you may have .
use of and / or registration on any portion of this site constitutes acceptance of our user agreement (updated 5 / 25 / 18) and privacy policy and cookie statement (updated 5 / 25 / 18) .
© 2018 advance local media llc. all rights reserved (about us). the material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of advance local .
community rules apply to all content you upload or otherwise submit to this site .
legal status (the legal status is an assumption and is not a legal conclusion. google has not performed a legal analysis and makes no representation as to the accuracy of the status listed. )
current assignee (the listed assignees may be inaccurate. google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list. )
priority date (the priority date is an assumption and is not a legal conclusion. google has not performed a legal analysis and makes no representation as to the accuracy of the date listed. )
chemical analysis of biological material, e. g. blood, urine; testing involving biospecific ligand binding methods; immunological testing
chemical analysis of biological material, e. g. blood, urine; testing involving biospecific ligand binding methods; immunological testing involving proteins, peptides or amino acids
medicinal preparations characterised by the non - active ingredients used, e. g. carriers or inert additives; targeting or modifying agents chemically bound to the active ingredient
medicinal preparations characterised by the non - active ingredients used, e. g. carriers or inert additives; targeting or modifying agents chemically bound to the active ingredient the non - active ingredient being chemically bound to the active ingredient, e. g. polymer - drug conjugates
medicinal preparations characterised by the non - active ingredients used, e. g. carriers or inert additives; targeting or modifying agents chemically bound to the active ingredient the non - active ingredient being chemically bound to the active ingredient, e. g. polymer - drug conjugates the non - active ingredient being a modifying agent
medicinal preparations characterised by the non - active ingredients used, e. g. carriers or inert additives; targeting or modifying agents chemically bound to the active ingredient the non - active ingredient being chemically bound to the active ingredient, e. g. polymer - drug conjugates the non - active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e. g. an oligomeric, polymeric or dendrimeric molecule
medicinal preparations characterised by the non - active ingredients used, e. g. carriers or inert additives; targeting or modifying agents chemically bound to the active ingredient the non - active ingredient being chemically bound to the active ingredient, e. g. polymer - drug conjugates the non - active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e. g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon - to - carbon unsaturated bonds, e. g. polyureas or polyurethanes
medicinal preparations characterised by the non - active ingredients used, e. g. carriers or inert additives; targeting or modifying agents chemically bound to the active ingredient the non - active ingredient being chemically bound to the active ingredient, e. g. polymer - drug conjugates the non - active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e. g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon - to - carbon unsaturated bonds, e. g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e. g. peg, ppg, peo or polyglycerol
immunoglobulins [ igs ], e. g. monoclonal or polyclonal antibodies against material from animals or humans
immunoglobulins [ igs ], e. g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
immunoglobulins [ igs ], e. g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
istituto di richerche di biologia molecolare p. angeletti s. p. a .
single - chain fv with manifold n - glycans as bifunctional scaffolds for immunomolecules .
html public
- / / w3c / / dtd html 3. 2 final / / en
mr. tooman has nearly 20 years of industry experience and has worked extensively in diverse pharmaceutical positions including, investor communications, strategic planning, finance, marketing, and sales. while at ilex, mr. tooman managed the formation of ilexs first comprehensive strategic plan and the restructuring of the companys clinical development activities to drive the companys transformation from a drug development contract research organization into a product - driven pharmaceutical company. mr. tooman was also charged with leading the integration of ilex and genzyme, a $ 1 billion transaction that maintained the majority of ilexs operations .
before joining ilex, mr. tooman worked at pharmacia corporation where he progressed through positions of increasing responsibility in investor relations including vice president of investor relations. in this role, he was responsible for global investor relations activities and spearheaded communications with the financial community on the pharmacia and upjohn / monsanto merger. additionally, under his leadership the investor relations unit of pharmacia won four of the largest awards of distinction in investor and public relations. mr. tooman has also held various management positions in europe and japan .
mr. tooman received a master of business administration degree in finance from the university of chicago and a bachelor of arts degree in economics from kalamazoo college .
all information in this press release is as of january 5, 2005 and the company undertakes no duty to update this information .
pegylation has successfully been used on various pharmaceutical compounds, including enzymes, peptides and antibodies, to improve their pharmaceutical properties through the chemical attachment of polyethylene glycol (peg) using our customized linker technology. pegylation technology employs proprietary chemical linkers designed to either release the native molecule at a controlled rate or provide permanent linkage that will maximize inherent activity of the native molecule. in some cases, pegylation can render a compound therapeutically effective, whereas the unmodified form had only limited clinical utility .
hisun is a leading biopharmaceutical group focused on improving patient wellbeing and quality of life. headquartered in taizhou (zhejiang, china), the company currently employs more than 3, 800 people. hisun’s operations strictly follow cgmp and received iso 14000 certification in 2001. to date, more than 40 of the company’s products have passed certification by the fda (us), edqm (eu), tga (australia), kfda (korea), etc. , and are sold in more than 30 countries. the company opened its u. s. headquarters in princeton, n. j. , in 2010. for more information, visit urltoken .
this press release contains, or may contain, forward - looking statements within the “safe harbor” provisions of the private securities litigation reform act of 1995. all statements contained in this press release, other than statements that are purely historical, are forward - looking statements, which can be identified by the use of forward - looking terminology such as the words “believes, ” “expects, ” “may, ” “will, ” “should, ” “potential, ” “anticipates, ” “plans, ” or “intends” and similar expressions .
through this transaction, belrose pharma has added to its portfolio both “traditional” permanent pegylation and the lesser - known releasable pegylation technologies, as well as compounds based on both technologies. polyethylene glycol (peg), when permanently linked to certain compounds, has a long track record of enabling high - value commercial products through sometimes dramatic improvements in in vivo circulation, toxicity, and efficacy. the lesser - known releasable pegylation technique provides a different set of clinical benefits – including several targeted release options without a corresponding reduction in potency, improved drug loading, pharmacokinetics, and efficacy, and a simplified and potentially shorter clinical path to market .
about belrose pharma inc. belrose pharma inc. (princeton, nj) is a specialty pharmaceutical company that operates two related businesses: (a) advancing development of internal clinical and pre - clinical compounds, and (b) product development for third party customers seeking to improve both early clinical and mid - lifecycle products using a range of technologies including customized linker technology®. belrose combines a new senior commercial management team with a core technical team previously involved in development and commercialization efforts using customized pegylation linker technologies. further information about belrose can be found on the company’s website at urltoken .
moody’s daily credit risk score is a 1 - 10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. the score provides a forward - looking, one - year measure of credit risk, allowing investors to make better decisions and streamline their work ow. updated daily, it takes into account day - to - day movements in market value compared to a company’s liability structure .
* copyright © 2018 insider inc. and urltoken gmbh (imprint). all rights reserved. registration on or use of this site constitutes acceptance of our terms of service, cookie policy, and privacy policy. disclaimer | commerce policy | made in nyc | stock quotes by urltoken need help? contact us !
this company is compared to stocks in the same industry. it is sorted by largest to the smallest market value. feel free to change the stock symbol and select the compare button .
this row includes the target price and the current last sale' s (cls') percent of the target price (tp). the target price is defined as the analyst estimated 1 year target price. the cls' percent of tp calculation is (current price / target price) * 100
and the% change of the 52 week high from the current last sale. the 52 week high is defined as the highest end of day value for the past year. the color coding assigns a value of' very positive' to' very negative'. the color key, below, indicates the assigned values and a possible explanation for the rating. however, it is important to note that each value should be looked at in combination with other factors. the stock comparison page should serve as one among many informational tools for comparing stocks and should not be the only basis for a buy or sell decision. advice from a securities professional is strongly advised. please
neutral: 10 to 15% (this means the stock is trading at a level that doesn' t provide any clear signal for price movement. )
negative: 16% to 30% (this indicates that the% decrease is at a level that may indicate a stock that lacks support for a higher stock price) .
more negative: 31 to 60% (this indicates that the% decrease is at a level that may indicate a stock that lacks support for a higher stock price) .
very negative: 61% and below (this indicates that the% decrease is at a level that may indicate a stock that lacks support for a higher stock price) .
and the% change of the 52 week low from the current last sale. the 52 week low is defined as the lowest end of day value for the past year. the color coding assigns a value of' very positive' to' very negative'. the color key, below, indicates the assigned values and a possible explanation for the rating. however, it is important to note that each value should be looked at in combination with other factors. the stock comparison page should serve as one among many informational tools for comparing stocks and should not be the only basis for a buy or sell decision. advice from a securities professional is strongly advised. please
. the beta is defined as a measure of the volatility of a stock relative to the overall market. a beta of less than one indicates lower risk than the market. a beta of more than one indicates higher risk than the market. urltoken uses the s & p 500 as the underlying index to measure the overall market for beta. the color coding assigns a value of very positive to very negative. the color key, below, indicates the assigned values and a possible explanation for the rating. however, it is important to note that each value should be looked at in combination with other factors. the stock comparison page should serve as one among many informational tools for comparing stocks and should not be the only basis for a buy or sell decision. advice from a securities professional is strongly advised. please
. the days to cover is calculated as the aggregate short interest for the month divided by the average daily share volume traded for the period between short interest settlement dates. days to cover is also referred to as' short - interest ratio'. the term' days to cover' was coined to indicate how many days it will take short sellers to cover their positions if the price of a stock rises. some investors see a high short interest as an opportunity; this is referred to as' short squeeze'. visit investopedia for more information about
. the color coding assigns a value of' very positive' to' very negative'. the color key, below, indicates the assigned values and a possible explanation for the rating. in this instance the rating is assuming that the person is the' short seller'. however, it is important to note that each value should be looked at in combination with other factors. the stock comparison page should serve as one among many informational tools for comparing stocks and should not be the only basis for a buy or sell decision. advice from a securities professional is strongly advised. please
please note: the sec has issued technical ammendments to the emergency short sale order that provided listing exchanges with guidance regarding which securities are covered by the order. nasdaq has posted a list of inculded financial firms for our market as well as a consolidated list for all exchanges. nasdaq continue to post updated lists on this page daily until the expiration of the emergency order .
very positive: 1 and lower (this indicates that the stock would take less than a day for short sellers to cover their positions .
positive: 1. 1 - 1. 5 (this indicates that the stock would take slightly longer than a day for short sellers to cover their positions .
neutral: 1. 6 - 2 (this indicates that the stock would take up to two days for short sellers to cover their positions .
negative: 2. 1 - 3 (this indicates that the stock would take more than a two days for short sellers to cover their positions .
more negative: 3 - 8 (this indicates that the stock would longer for short sellers to cover their positions .
very negative: 9 and above (this indicates that the stock would take much longer for short sellers to cover their positions .
. the p / e is defined as the stock analysis statistic in which the current price of a stock (today' s current last sale price) is divided by the reported actual (or sometimes projected, which would be forecast) earnings per share of the issuing firm; it is also called the' multiple'. visit urltoken to read about
. the color coding assigns a value of' very positive' to' very negative'. the color key, below, indicates the assigned values and a possible explanation for the rating. a low p / e might indicate a number of negative factors, including, but not limited to projected lower earnings. however, it is important to note that each value should be looked at in combination with other factors. the stock comparison page should serve as one among many informational tools for comparing stocks and should not be the only basis for a buy or sell decision. advice from a securities professional is strongly advised. please
enzon pharmaceuticals , inc is a pharmaceutical company engaged in developing therapeutics to patients whose needs are unmet . its headquarters is now in piscataway , new jersey . the company is a publicly traded company on nasdaq under the symbol " enzn " . it 's also doing marketing works in asia areas such as china . in 2012 , the company orally presented in nanjing , china about the symposium of its drug delivery systems , which help improve therapeutic molecules ' pharmaceutical properties . 
enzon pharmaceuticals, inc is a pharmaceutical company engaged in developing therapeutics to patients whose needs are unmet. its headquarters is now in piscataway, new jersey. the company is a publicly traded company on nasdaq under the symbol " enzn ". it's also doing marketing works in asia areas such as china. in 2012, the company orally presented in nanjing, china about the symposium of its drug delivery systems, which help improve therapeutic molecules' pharmaceutical properties.
enzon pharmaceuticals, inc is a pharmaceutical company engaged in developing therapeutics to patients whose needs are unmet. its headquarters is now in piscataway, new jersey. the company is a publicly traded company on nasdaq under the symbol " enzn ". it's also doing marketing works in asia areas such as china. in 2012, the company orally presented in nanjing, china about the symposium of its drug delivery systems, which help improve therapeutic molecules' pharmaceutical properties.